Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722408 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
A Phase 2 study of Hypercholesteremia, sponsored by NeuroBo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 7
- Study locations
NCT02722408: Completed Phase 2 study of Hypercholesteremia, sponsored by NeuroBo Pharmaceuticals.
NCT02722408 is a Phase 2 study of Hypercholesteremia that has completed, run by NeuroBo Pharmaceuticals. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02722408, a Phase 2 study of Hypercholesteremia, has completed, sponsored by NeuroBo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.
Conditions Studied
Interventions
- DRUG Gemcabene
Study Locations (7)
Other
- Wolfson Medical Center Internal Medicine Dept. - Holon
- Center for Research, Prevention and Treatment of Atherosclerosis - Cardiology Department of Medicine Kiryat Hadassah - Jerusalem
- Ziv Medical Center Internal Medicine Department - Safed
Quebec
- Ecogene-21 - Chicoutimi
- Montreal Heart Institute - Montreal
California
- Westside Medical Associates of Los Angeles - Beverly Hills
Ontario
- Robarts Research Institute - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
What the finished NCT02722408 record still lists
NCT02722408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Hypercholesteremia appearing as the primary indexed condition, and to 1 intervention - of which Gemcabene is the first listed.
NCT02722408 lists 7 locations in 4 states (Other, Quebec, California).
Frequently Asked Questions
What is clinical trial NCT02722408 about?
NCT02722408 is a clinical study titled "Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)". The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.
What is the current status of trial NCT02722408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-06. Estimated completion is 2017-07.
What conditions does trial NCT02722408 study?
This clinical trial studies the following conditions: Hypercholesteremia.
What interventions are being tested in trial NCT02722408?
The interventions under investigation include: Gemcabene (DRUG).
Who is sponsoring clinical trial NCT02722408?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02722408 being conducted?
This trial has 7 study locations across California, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02722408's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia